1. Introduction {#sec0005}
===============

Flow cytometry (FC) is a widely adopted technology with several applications, mainly for the evaluation of cell properties (*i.e.* size and granularity), which are evaluated by detection of intrinsic or extrinsic fluorescence used to identify a large number of molecules. FC allowed the development of bioassays based on different mechanisms of action that result in cell proliferation, cytotoxicity, apoptosis and specific cytokine expression \[[@bib0005]\].

The main disadvantages of conventional flow cytometry are the significant delays related to saving individual sample associated files, and in the cell suspension sampling mechanism, which frequently involves time-consuming steps such as tube priming and flushing \[[@bib0010]\].

The evolution to high-throughput flow cytometry (HTFC) extends the capabilities of cell-based screening technologies. IntelliCyt iQue Screener PLUS® is a novel technological breakthrough that established the application of rapid flow cytometry by combining fast sample delivery with information-rich data on a cell-by-cell basis. This technology has several advantages, such as rate of analysis, small sample volumes and automated sample processing. This allows exploring applications in small molecule drug discovery and biotherapeutics. HTFC is used extensively in antibody screening, in order to select candidates with specific and optimized mechanism of action (MOA) and to detect structural modifications that could impact the biological activity \[[@bib0015], [@bib0020], [@bib0025]\].

Antibody-dependent cell-mediated cytotoxicity (ADCC) assays are essential to demonstrate primary *in vitro* studies for the clinical efficacy of many immunotherapies \[[@bib0030]\]. In a previous stage we developed and validated an ADCC assay to test the efficacy and potency of biopharmaceutical products, demonstrating cell death on target cells by membrane permeability using conventional flow cytometry \[[@bib0035]\]. Based on our experience in the development and validation of bioassays under GLP-cGMP environment, here we transferred our ADCC assay to a high-throughput technology, IntelliCyt iQue Screener PLUS®, by evaluating cell membrane permeability, caspase activation and phosphatidyl serine exposure as characteristics of death on target cells in the same sample with low volume of acquisition.

2. Materials and methods {#sec0010}
========================

2.1. Assay preparation {#sec0015}
----------------------

The preparation of the assay was based on the conditions we previously established for the ADCC assay using conventional flow cytometry \[[@bib0035]\]. In brief:

### 2.1.1. Preparation of cells {#sec0020}

Primary NK cells were isolated from peripheral blood from donors using negative selection by MACS® (Myltenyi Biotec, Bergisch Gladbach, Germany). We used Daudi Burkitt's lymphoma cells (ATCC, Manassas, VA, USA) as target cells which were cultured in RPMI medium (GIBCO, NY. USA.) supplemented with fetal bovine serum (GIBCO, NY. USA.) and were harvested at 80 % of confluence. These samples were obtained from volunteers, who signed an informed consent according to an internal procedure.

### 2.1.2. Formation of ADCC complex {#sec0025}

Serial independent dilutions of rituximab (F. Hoffmann-La Roche Ltd. Basel, Switzerland) were prepared and incubated during 30 min along with the target cells (1 × 10^5^ cells/mL) in 96-well plates. Then, the effector cells were dispensed to the wells and cocultured for 4 h. The dose response curve was established 0.00013--1300 μg/mL with a 1:4 effector / target cells ratio.

2.2. Detection of cell death by flow cytometry {#sec0030}
----------------------------------------------

Cell death was determined by three different indicators: cell permeability, caspase activation and phosphatidyl serine exposure. Cell viability was determined as membrane integrity by inability to exclude a DNA binding dye due to compromises porous membrane using the FL3 detection channel. Caspase 3 and 7 activation was detected using the NucView® 488 Caspase-3/7 substrate, which upon cleavage by activated enzyme, results in a fluorescent signal detected by FL1 channel. Phosphatidyl serine exposure was detected by the binding of Annexin V to the cell surface detected by FL2 channel.

All the reagents we used to determine cell death were provided by Sartorius as part of the MultiCyt Apoptosis Kit (Sartorius, Göttingen, Germany). The IntelliCyt® iQue Screener PLUS® acquisition parameters used here were customized for the MultiCyt cell-based kit and preloaded to the instrument by the supplier.

2.3. Validation {#sec0035}
---------------

The validation exercise focused on the assessment of: 4 PL fitting, specificity (against matrix), precision, and accuracy according to the ICH Q2 (R1) guideline and the USP \<1033\> Biological Assay Validation Chapter \[[@bib0040],[@bib0045]\]. Statistical analyses were performed using the Graph Pad Prism 6.0 software (La Jolla, CA). All the experiments were performed by independent triplicates.

3. Results and discussion {#sec0040}
=========================

In a previous report, we developed and validated an ADCC assay as per international guidelines, which could be implemented to evaluate different biopharmaceutical molecules bearing an Fc region \[[@bib0035]\].

Here we extrapolated our ADCC assay to a high-throughput flow cytometry system using the cell death characteristics of membrane permeability, caspase activation and phosphatidyl serine exposure as ADCC response on target cells.

We observed a sigmoidal curve dependent on rituximab concentration with the three evaluated parameters. As shown in the [Fig. 1](#fig0005){ref-type="fig"} the dose-response curves fitted to the 4 PL model (r^2^ \> 0.90) in all cases ([Fig. 1](#fig0005){ref-type="fig"}a, b, c).Fig. 1High-throughput flow cytometric analysis of death target cells by ADCC. Daudi cells were harvested and culture with rituximab and primary NK cells for ADCC assay as indicated in methodology. Cell death was determined by (a) caspase activation, (b) phosphatidyl serine exposure and (c) cell permeability. Black lines indicate the rituximab response at different concentrations while grey lines correspond to adalimumab (negative control). Error bars represent the standard deviation at each concentration level.Fig. 1

The coefficients of variation at each concentration level were \< 20 %. Specificity was confirmed by fitting the sigmoidal dose-response of adalimumab, as expected adalimumab recognized membrane-bound Tumor Necrosis Factor α (mTNF-α) expressed in the engineered CHO-K1 cells, and triggered the ADCC mechanism of action mediated by primary NK cells, unlike the negative control rituximab, which is targeted toward CD20, commonly expressed by B cells. Accuracy was determined by dilutional linearity evaluated in a dilutional range of sample recoveries at 60, 100 and 140 %. Among the three methods we used to determine cell death, annexin was selected to determine accuracy because exhibited the best linear behavior, which is desirable for assays intended to be used as routine tests for quality control purposes ([Fig. 2](#fig0010){ref-type="fig"}). However, the other two determinations, cell permeability and caspase activation, could be also valuable to confirm the ADCC response making adjustments to achieve a suitable linear response. A summary of results is found in [Table 1](#tbl0005){ref-type="table"}, we concluded that the three parameters demonstrated to be suitable for the assessment of ADCC.Fig. 2Accuracy of Annexin positive cells in response to rituximab. Accuracy was determined by dilutional linearity evaluated in a dilutional range of sample recoveries at 60, 100 and 140 %. Relationship between nominal and measured potency (EC50, r^2^ = 0.97, slope: 0.92).Fig. 2Table 1Measured validation parameters for ADCC induced by rituximab.Table 1CharacteristicParameterAcceptance criteriaResults**4 PL model fitting**Fitting to the 4 PL model^a^r^2^ ≥ 0.90CaspaseAnnexinNon-viable0.96[a](#tblfn0005){ref-type="table-fn"}0.90[a](#tblfn0005){ref-type="table-fn"}0.91[a](#tblfn0005){ref-type="table-fn"}**Specificity**Fitting of the positive sample to the 4 PL modelr^2^ ≥ 0.90r^2^ ≥ 0.90[a](#tblfn0005){ref-type="table-fn"}Negative sample do not fit 4 PLCurve profileDid not fit**Precision**Repeatability^b^: Coefficient of variation (% CV) among independent triplicates at each concentration level of the dose-response curve≤ 20.0 %CaspaseAnnexinNon-viable1.4--13.6 %2.1--18.9 %3.5--18.3 %**Accuracy**Correspondence between the nominal potency and the measured potency obtained from dilutional linearityr^2^ ≥ 0.900.97[c](#tblfn0015){ref-type="table-fn"}Slope of relative potency *vs* nominal potency0.70 - 1.300.92[c](#tblfn0015){ref-type="table-fn"}**System suitability**Ratio between maximum response / minimum response of the positive sample\> 2.0CaspaseAnnexinNon-viable6.55.29.5Fitting to the 4 PL model in a rituximab concentration range of the 1.3 × 10^−5^ -1.3 × 10^3^ μg/mLr^2^ ≥ 0.90r^2^ ≥ 0.90[a](#tblfn0005){ref-type="table-fn"}Repeatability≤ 20.0 %≤ 20.0 %[b](#tblfn0010){ref-type="table-fn"}[^2][^3][^4]

The comparison of the results we obtained in a previous validated study using conventional FC detection \[[@bib0035]\] *versus* the HTFC results obtained here by evaluating the same attribute (cell permeability) and demonstrate that both methodologies complied with the pre-established acceptance criteria and are suitable for their intended use. As expected, automation of IntelliCyt iQue Screener PLUS® has the advantage of harnessing low sample volume more rapidly, thus decreasing variability in the acquisition and reducing the data analysis time. These advantages resulted in an increase in the number of tested samples without compromising the reliability of results.

4. Conclusions {#sec0045}
==============

The capabilities of the analytical platform of IntelliCyt iQue Screener PLUS® are suitable for the development of bioassays. In this study, we demonstrated that previous validated ADCC assay could be transferred to a high-throughput system that is also suitable for as an alternative for characterization and batch release purposes of biotherapeutic products such as rituximab under regulated environments. In this sense, there is a potential variety of applications that could be implemented to evaluate different MOA of biotherapeutics *in vitro*.
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